• Enanta outlined upcoming ESCMID Global 2026 presentations on zelicapavir, an oral once-daily RSV drug candidate, with data scheduled for April 18, 2026.
• One presentation will feature Phase 2b results in high-risk adults that were previously disclosed in September 2025.
• Those results showed faster complete symptom resolution, lower hospitalization rates, improved viral load outcomes.
• A second presentation will cover pediatric Phase 2 findings previously disclosed in September 2024.
• The pediatric data support a high barrier to antiviral resistance, a potential differentiator for longer-term use and broader patient adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260407155688) on April 07, 2026, and is solely responsible for the information contained therein.